Barclays PLC Increases Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Barclays PLC lifted its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 2,044.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,625 shares of the company's stock after buying an additional 19,663 shares during the quarter. Barclays PLC's holdings in Immunocore were worth $608,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in IMCR. China Universal Asset Management Co. Ltd. boosted its position in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after acquiring an additional 960 shares during the period. NEOS Investment Management LLC boosted its position in shares of Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after acquiring an additional 1,102 shares during the period. Assetmark Inc. boosted its position in shares of Immunocore by 5.3% in the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company's stock valued at $949,000 after acquiring an additional 1,616 shares during the period. Geode Capital Management LLC boosted its position in shares of Immunocore by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock valued at $1,047,000 after acquiring an additional 420 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its position in shares of Immunocore by 36.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock valued at $1,121,000 after acquiring an additional 10,217 shares during the period. 84.50% of the stock is owned by institutional investors.

Immunocore Trading Down 5.1%

NASDAQ:IMCR traded down $1.51 on Tuesday, reaching $28.03. 71,587 shares of the stock traded hands, compared to its average volume of 428,637. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -29.50 and a beta of 0.75. The company's 50 day moving average is $28.80 and its 200-day moving average is $30.11. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 1-year low of $23.15 and a 1-year high of $59.82.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million during the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company's quarterly revenue was up 33.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.49) EPS. Equities research analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Insider Transactions at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the transaction, the director now owns 2,144,060 shares in the company, valued at $63,721,463.20. This trade represents a 60.40% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IMCR shares. Needham & Company LLC reiterated a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, April 10th. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Oppenheimer increased their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 target price on shares of Immunocore in a report on Friday, March 7th. Finally, Mizuho lowered their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Immunocore currently has a consensus rating of "Moderate Buy" and an average price target of $58.13.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.